more common if paired with insulin or sulfonylureas
While these findings are observational and require confirmation in prospective studies, they highlight the potential of GLP-1 therapies to influence long-term musculoskeletal and inflammatory outcomes in patients with diabetes. For more information: Betul Ibis, MD, can be reached at [email protected].
The sites are the same, and the delivery device is what changes
Musso G, Saba F, Cassader M, Gambino R
First, we need to decide if someone is actually in a plateau
Excess adiposity causes glucagon resistance, and leads to MASLD by reducing lipid metabolism in the liver